"When the 500's first-half price gain was between 7% and 12%?the market went on to record an average price rise of 5.1% during the second half and posted a positive performance an above-average 87% of the time," wrote CFRA's Chief Investment Strategist, Sam Stovall.
RDI Initiates Coverage on:
Exelixis, Inc.
https://ub.rdinvesting.com/news/?ticker=EXEL
Seattle Genetics
https://ub.rdinvesting.com/news/?ticker=SGEN
Exelixis' stock moved 4.71% higher Monday, to close the day at $24.90. The stock recorded a trading volume of 6,110,490 shares, which was above its three months average volume of 3,311,770 shares. In the last year Exelixis Inc.'s shares have traded in a range of 7.20 - 25.18. The share price has gained 245.83% from its 52 week low. The company's shares are currently trading above their 200-day moving average. Moreover, the stock's 50-day moving average of $20.39 is greater than its 200-day moving average of $19.92. Shares of Exelixis have gained approximately 67.0 percent year-to-date.
Access RDI's Exelixis Research Report at:
https://ub.rdinvesting.com/news/?ticker=EXEL
On Monday, shares in Seattle Genetics recorded a trading volume of 8,174,482 shares, which was above the three months average volume of 702,105 shares. The stock ended the day 8.41% lower at 56.55. The share price has gained 57.39% from its 52 week low with a 52 week trading range of 35.93 - 75.36.The company's shares are currently trading below their 200-day moving average. Moreover, the stock's 50-day moving average of $63.99 is greater than its 200-day moving average of $63.11. Shares of Seattle Genetics have gained approximately 7.16 percent year-to-date.
Access RDI's Seattle Genetics Research Report at:
https://ub.rdinvesting.com/news/?ticker=SGEN
Our Actionable Research on Exelixis, Inc. (NASDAQ: EXEL) and Seattle Genetics, Inc. (NASDAQ: SGEN) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
contact@rdinvesting.com
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com